Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (NCT07735377) titled 'A Multicenter, Open-label Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of SHR-6914 Injection in Participants With Prostate Cancer' on July 24.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Condition:
Prostate Cancer
Intervention:
Drug: SHR-6914
Recruitment Status: Not recruiting
Phase: Phase 1
Date of First Enrollment: August 2026
Target Sample Size: 118
Countries of Recruitment:
China...